Enlicitide (Lipfendra): the first oral PCSK9 inhibitor - from macrocyclic peptide innovation to clinical translation
A substantial proportion of patients with hypercholesterolaemia, particularly those with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolaemia (HeFH), do not achieve recommended LDL-cholesterol (LDL-C) targets despite statins, ezetimibe, and injectable PCSK9 inhibitors. The paren...